BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27146587)

  • 1. Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.
    Molinaro AM; Sison JD; Ljung BM; Tlsty TD; Kerlikowske K
    Breast Cancer Res Treat; 2016 Jun; 157(2):351-361. PubMed ID: 27146587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
    Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
    J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS.
    Nekhlyudov L; Habel LA; Achacoso N; Jung I; Haque R; Collins LC; Schnitt SJ; Quesenberry CP; Fletcher SW
    J Natl Cancer Inst; 2012 Apr; 104(8):614-21. PubMed ID: 22491230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ductal carcinoma in situ, complexities and challenges.
    Leonard GD; Swain SM
    J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
    Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
    Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
    Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 10. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast.
    Neuschatz AC; DiPetrillo T; Steinhoff M; Safaii H; Yunes M; Landa M; Chung M; Cady B; Wazer DE
    Cancer; 2002 Apr; 94(7):1917-24. PubMed ID: 11932892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
    Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
    J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
    Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
    Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
    Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
    J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast.
    Rivera R; Banks A; Casillas-Lopez A; Rashtian A; Lewinsky B; Sheth P; Hovannesian-Larsen L; Brousseau D; Iyengar G; Holmes DR
    Breast J; 2016; 22(1):63-74. PubMed ID: 26534876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of local recurrence following excision alone for ductal carcinoma in situ.
    Hetelekidis S; Collins L; Silver B; Manola J; Gelman R; Cooper A; Lester S; Lyons JA; Harris JR; Schnitt SJ
    Cancer; 1999 Jan; 85(2):427-31. PubMed ID: 10023711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
    Tunon-de-Lara C; Giard S; Buttarelli M; Blanchot J; Classe JM; Baron M; Monnier B; Houvenaeghel G
    Breast J; 2008; 14(2):135-40. PubMed ID: 18315691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
    Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
    Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
    Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
    Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.